Skip to main content
JAMA Network logoLink to JAMA Network
. 2024 Jul 22;184(9):1137. doi: 10.1001/jamainternmed.2024.3735

Errors in Figure 2

PMCID: PMC11264073  PMID: 39037781

In the Original Investigation titled “Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: the STOP-PASC Randomized Clinical Trial,”1 published online on June 7, 2024, in JAMA Internal Medicine, the dashed lines to indicate 15 days and 10 weeks were not properly aligned with the x-axis labels. This article was corrected online.

Reference

  • 1.Geng LN, Bonilla H, Hedlin H, et al. Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial. JAMA Intern Med. Published online June 7, 2024. doi: 10.1001/jamainternmed.2024.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Internal Medicine are provided here courtesy of American Medical Association

RESOURCES